Current Trends and Advancements in the Management of Hepatocellular Carcinoma.

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-04-10 DOI:10.1159/000538815
A. Teufel, Masatoshi Kudo, Yuquan Qian, J. Daza, Isaac Rodriguez, Christoph Reissfelder, E. Ridruejo, M. P. Ebert
{"title":"Current Trends and Advancements in the Management of Hepatocellular Carcinoma.","authors":"A. Teufel, Masatoshi Kudo, Yuquan Qian, J. Daza, Isaac Rodriguez, Christoph Reissfelder, E. Ridruejo, M. P. Ebert","doi":"10.1159/000538815","DOIUrl":null,"url":null,"abstract":"Hepatocellular Carcinoma (HCC) remains a significant global health burden with a high mortality rate. Over the past 40 years, significant progress has been achieved in the prevention and management of HCC. Hepatitis B vaccination programs, the development of direct acting antiviral drugs for Hepatitis C and effective surveillance strategies provide a profound basis for prevention for HCC. Advanced surgery and liver transplantation along with local ablation techniques potentially offer cure for the disease, Also just recently, the introduction of immunotherapy opened a new chapter in systemic treatment. Finally, the introduction of the BCLC classification system for HCC, clearly defining patient groups and assigning reasonable treatment options, has standardized treatment and become the basis of almost all clinical trials for HCC. With this review, we provide a comprehensive overview of the evolving landscape of HCC management but also touch on current challenges. A comprehensive and multidisciplinary approach is crucial for effective HCC management. Continued research and clinical trials are imperative to further enhance treatment options and will ultimately reduce the global burden of this devastating disease.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"515 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538815","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular Carcinoma (HCC) remains a significant global health burden with a high mortality rate. Over the past 40 years, significant progress has been achieved in the prevention and management of HCC. Hepatitis B vaccination programs, the development of direct acting antiviral drugs for Hepatitis C and effective surveillance strategies provide a profound basis for prevention for HCC. Advanced surgery and liver transplantation along with local ablation techniques potentially offer cure for the disease, Also just recently, the introduction of immunotherapy opened a new chapter in systemic treatment. Finally, the introduction of the BCLC classification system for HCC, clearly defining patient groups and assigning reasonable treatment options, has standardized treatment and become the basis of almost all clinical trials for HCC. With this review, we provide a comprehensive overview of the evolving landscape of HCC management but also touch on current challenges. A comprehensive and multidisciplinary approach is crucial for effective HCC management. Continued research and clinical trials are imperative to further enhance treatment options and will ultimately reduce the global burden of this devastating disease.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝细胞癌治疗的当前趋势和进展。
肝细胞癌(HCC)仍然是全球健康的重大负担,死亡率很高。过去 40 年来,HCC 的预防和管理取得了重大进展。乙型肝炎疫苗接种计划、丙型肝炎直接作用抗病毒药物的开发以及有效的监测策略为预防 HCC 提供了深厚的基础。先进的外科手术和肝移植以及局部消融技术有可能治愈这种疾病,而且就在最近,免疫疗法的引入为全身治疗揭开了新的篇章。最后,BCLC HCC 分类系统的引入,明确定义了患者分组并分配了合理的治疗方案,规范了治疗,几乎成为所有 HCC 临床试验的基础。通过这篇综述,我们全面概述了不断发展的 HCC 治疗情况,同时也谈到了当前面临的挑战。综合的多学科方法对于有效治疗 HCC 至关重要。持续的研究和临床试验对于进一步改进治疗方案势在必行,并将最终减轻这种毁灭性疾病给全球带来的负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊介绍: ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.
期刊最新文献
Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed Leishmania donovani Antigen Immunomodulatory System in Visceral Leishmaniasis. Biocompatible Lubricant-Coated Flexible Neural Probes with Enhanced Long-Term Recording Stability. One-Step Pulsed Electrodeposition of ZnO/ZnP Composite Coatings on Titanium Implants for Enhanced Antibacterial Activity and Biocompatibility. Plasmonic Nanotheranostics: Merging Imaging and Therapy on a Unified Platform for Precision Oncology. Smart Macrocycles: Cyclodextrin-Porphyrin Photosensitizers for Photodynamic Therapy in Human Bladder Cancer Cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1